Publications
RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors." Nature communications 9, no. 1 (2018).
"Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing." Methods Mol Biol 1767 (2018): 447-480.
"Synthetic transcription factors for cell fate reprogramming." Current opinion in genetics & development 52 (2018): 13-21.
"Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic acids research 45, no. 20 (2017).
"CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues." Arthritis & rheumatology (Hoboken, N.J.) 69, no. 5 (2017): 1111-1121.
"CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nat Biotechnol 35, no. 6 (2017): 561-568.
"Editorial Overview: Synthetic biology and biomedical engineering." Current Opinion in Biomedical Engineering 4 (2017): vi - vii.
"An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis." ACS synthetic biology 6, no. 11 (2017): 2003-2013.
"Expanding the CRISPR Toolbox: Targeting RNA with Cas13b." Molecular cell 65, no. 4 (2017): 582-584.
"Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nat Commun 8 (2017).
"Genetic engineering: Chemical control for CRISPR editing." Nature chemical biology 13, no. 1 (2017): 2-3.
"Genome engineering: a new approach to gene therapy for neuromuscular disorders." Nature reviews. Neurology 13, no. 11 (2017): 647-661.
"Genome Engineering for Personalized Arthritis Therapeutics." Trends in molecular medicine 23, no. 10 (2017): 917-931.
"Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs." Stem cell reports 8, no. 5 (2017): 1202-1213.
"Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies." Nucleic Acids Res 45, no. 20 (2017): 11684-11699.
"Loss-of-function genetic tools for animal models: cross-species and cross-platform differences." Nature reviews. Genetics 18, no. 1 (2017): 24-40.
"Mammalian Synthetic Biology: Engineering Biological Systems." Annual review of biomedical engineering 19 (2017): 249-277.
"* CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments." Tissue engineering. Part A 23, no. 15-16 (2017): 738-749.
"Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of the United States of America 113, no. 31 (2016): E4513-E4522.
"Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
"Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 71-88.
"The Development of TALE Nucleases for Biotechnology." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 27-42.
"Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochem Biophys Res Commun 478, no. 3 (2016): 1484-1490.
"Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature methods 13, no. 2 (2016): 127-137.
"Engineering Delivery Vehicles for Genome Editing." Annual review of chemical and biomolecular engineering 7 (2016): 637-662.
"